Resumen
Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 1017-1023 |
| Número de páginas | 7 |
| Publicación | Cleveland Clinic Journal of Medicine |
| Volumen | 68 |
| N.º | 12 |
| DOI | |
| Estado | Published - 2001 |
ASJC Scopus subject areas
- General Medicine
Huella
Profundice en los temas de investigación de 'GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver